Frederick J. Ruegsegger
Corporate Officer/Principal en Four Oaks Partners LLC .
Cargos activos de Frederick J. Ruegsegger
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| Four Oaks Partners LLC | Corporate Officer/Principal | 01/04/2012 | - |
Historial de carrera de Frederick J. Ruegsegger
Antiguos cargos conocidos de Frederick J. Ruegsegger.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
Novacea, Inc.
 Novacea, Inc. Pharmaceuticals: MajorHealth Technology Novacea, Inc. is a privately held biopharmaceutical company focused on licensing, developing and commercializing novel agents to revolutionize the treatment of cancer. Novacea’s in-licensed product portfolio features three clinical stage oncology therapeutics. The Company has two products which are anticipated to commence Phase 3 clinical trials in 2006, DN-101 and vinorelbine oral. Banoxantrone (AQ4N) is in Phase 1/2 clinical trials. It is located in South San Francisco, CA. | Director/Miembro de la Junta | 01/02/2008 | 03/02/2009 |
| ION BEAM APPLICATIONS, SA | Director Financiero/CFO | 01/06/2004 | 01/06/2004 |
| Oficial de Recursos Humanos | 01/06/2004 | 01/06/2004 | |
| Neoforma.com, Inc. | Director Financiero/CFO | 01/08/1999 | 01/10/2000 |
Axys Pharmaceuticals, Inc.
 Axys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Axys Pharmaceuticals, Inc. engages in the development of integrated drugs. The company is headquartered in South San Francisco, CA. | Director Financiero/CFO | 01/12/1996 | 01/07/1999 |
EyeSys Technologies, Inc.
 EyeSys Technologies, Inc. Medical SpecialtiesHealth Technology EyeSys Technologies, Inc. develops corneal topography systems. The company is based in Houston, TX. EyeSys Technologies was acquired by Premier Laser Systems, Inc. on October 01, 1997 for $12 million. | Presidente | 01/07/1993 | 01/12/1996 |
| Vitaphore Corp. | Presidente | 01/01/1991 | 01/06/1993 |
Transcept Pharma, Inc.
 Transcept Pharma, Inc. Pharmaceuticals: MajorHealth Technology Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. Its product pipeline is TO-2070, a novel, rapidly absorbed treatment for acute migraine incorporating dihydroergotamine as the active drug. The company was founded on January 30, 2009 and is headquartered in Point Richmond, CA. | Director/Miembro de la Junta | 22/07/2009 | - |
| Independent Dir/Board Member | 31/10/2011 | - | |
Sotera Health LLC
 Sotera Health LLC Medical/Nursing ServicesHealth Services Sotera Health LLC offers sterilization services. It offers medical device sterilization, pharmaceutical sterilization, food and commercial products safety, packaging materials, laboratory testing, and consulting services. The company was founded in 2017 and is headquartered in Broadview Heights, OH. | Director Financiero/CFO | 01/06/2004 | - |
Formación de Frederick J. Ruegsegger.
| University of Illinois | Undergraduate Degree |
| Kellogg School of Management | Graduate Degree |
Estadísticas
Internacional
| Estados Unidos | 11 |
| Bélgica | 2 |
Operativa
| Director of Finance/CFO | 4 |
| Director/Board Member | 2 |
| President | 2 |
Sectorial
| Health Technology | 7 |
| Consumer Services | 3 |
| Health Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| ION BEAM APPLICATIONS, SA | Health Technology |
| Empresas privadas | 8 |
|---|---|
Sotera Health LLC
Sotera Health LLC Medical/Nursing ServicesHealth Services Sotera Health LLC offers sterilization services. It offers medical device sterilization, pharmaceutical sterilization, food and commercial products safety, packaging materials, laboratory testing, and consulting services. The company was founded in 2017 and is headquartered in Broadview Heights, OH. | Health Services |
Novacea, Inc.
Novacea, Inc. Pharmaceuticals: MajorHealth Technology Novacea, Inc. is a privately held biopharmaceutical company focused on licensing, developing and commercializing novel agents to revolutionize the treatment of cancer. Novacea’s in-licensed product portfolio features three clinical stage oncology therapeutics. The Company has two products which are anticipated to commence Phase 3 clinical trials in 2006, DN-101 and vinorelbine oral. Banoxantrone (AQ4N) is in Phase 1/2 clinical trials. It is located in South San Francisco, CA. | Health Technology |
| Neoforma.com, Inc. | Health Technology |
Axys Pharmaceuticals, Inc.
Axys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Axys Pharmaceuticals, Inc. engages in the development of integrated drugs. The company is headquartered in South San Francisco, CA. | Health Technology |
EyeSys Technologies, Inc.
EyeSys Technologies, Inc. Medical SpecialtiesHealth Technology EyeSys Technologies, Inc. develops corneal topography systems. The company is based in Houston, TX. EyeSys Technologies was acquired by Premier Laser Systems, Inc. on October 01, 1997 for $12 million. | Health Technology |
| Vitaphore Corp. | |
Transcept Pharma, Inc.
Transcept Pharma, Inc. Pharmaceuticals: MajorHealth Technology Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. Its product pipeline is TO-2070, a novel, rapidly absorbed treatment for acute migraine incorporating dihydroergotamine as the active drug. The company was founded on January 30, 2009 and is headquartered in Point Richmond, CA. | Health Technology |
| Four Oaks Partners LLC |
